Good Progress But Challenges Remain For Japan’s AMED
This article was originally published in PharmAsia News
Executive Summary
Japan's year-old AMED is "now looking at how to expand its budget" and seeking new routes of cooperation, as it aims to foster better coordinated basic medical research between industry, academia and public institutes in the country.
You may also be interested in...
Japan Builds Asia Links Through New AMED Programs
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.